Agents and Actions

Editors
K. Brune (Executive Editor)
R. Hess
A. Lewis
W. Lorenz
P. May
I. Otterness
M. Parnham
B. Vargaftig

Index to volume 21, 1987

Birkhäuser Verlag
CH-4010 Basel (Switzerland)
© 1987

Author Index

Ackerman, N.R., 293, 334, 358
Adnot, S., 195
Agins, A.P., 397, 400
Agoston, S., 54
Ahnfelt-Rønne, I., 191
Aihara, Hironaka, 130
Aksulu, H.E., 184
Allec, J., 247
Alloatti, G., 72
Amano, T., 167
Argenbright, L.W., 310
Arner, E.C., 334

Bailey, P., 310
Bailly, J., 290
Ballaron, S.A., 281
Barrett, M., 160
Barrie, S.A., 223
Barron, P.C., 223
Barth, H., 1
Bartlett, R.R., 284
Bast, A., 41
Beninatti, L., 320
Bennett, M.K., 253, 272
Berkenkopf, J.W., 351
Berner, P.R., 345
Bertin, B., 262
Bhalara, D.D., 38
Bille-Hansen, V., 177
Bloxham, D.P., 323
Bluestein, J.G., 266
Bobovski, T.P., 253
Bonney, R.J., 310
Böttcher, I., 235
Bouclier, M., 238
Brune, K., 232
Brzezińska-Blaszczyk, E., 26
Buré, J., 262
Bürger, W., 93
Buyniski, J.P., 241

Caccese, R.G., 328
Calhoun, W., 306
Camussi, G., 72
Campbell, Jr., G.K., 303
Capiris, T., 253
Capsoni, F., 121
Carlson, R.P., 306, 379
Carney, S.L., 287
Carter, G.W., 366
Carty, T.J., 393
Cavey, D., 247
Champion, T.M., 244
Chang, J., 306, 320, 345, 379
Chanoine, F., 262
Chatelus, A., 238, 247
Chiba, K., 250
Chow, G., 387
Ciuffetelli, Jr., A., 293
Conaty, J.M., 328, 331
Cooke G.M., 358
Cooper, D.M., 260
Corry, D.G., 299
Cullinan, C.A., 351
Czuwaj, M., 26

Dahlgren, C., 104
Dai, S., 66
Darnell, L.R., 334
De Brito, F.B., 287, 299
De Young, L.M., 325
Dea, D., 331
DeLeon, R., 387
Delescluse, C., 290
Delhagen, J.E., 400
Demirel, E., 184
Desiderio, M.A., 49
Dieppe, P.A., 355
DiMartino, M.J., 303, 348
DiPasquale, G., 328, 331
Dixon, J.S., 89
Dondero, C., 361
Dong, M.K., 253, 272

Emanuelli, G., 72
Ercan, Z.S., 184
Ernest, M.J., 393
Eskra, J.D., 393
Eustache, J., 238
Evers, C.J., 281
Ezer, E., 173

Farina, P.R., 257, 387
Fefer, D., 358
Felmayer, G., 203
Fey, R.A., 366
Fleisch, J.H., 275
Floersheim, G.F., 217
Foster, St.J., 355
Fox, J.L., 366

Galbraith, W., 334
Gilbertsen, R.B., 253, 272
Gilman, S.C., 266, 345
Glinka, S., 310
Goldberg, R.L., 341
Golden, H.W., 371
Gomes, E.T., 62
Goodson, T., 275
Gorski, J.P., 149
Goyal, R.K., 38
Grüninger, M., 235
Gylys, J.A., 241

Hall, H.D., 293
Hanna, N., 303, 348
Hashimoto, Sanae, 130
Haston, W.O., 375
Hayashi, I., 384
Hayashi, M., 384
Henderson, B., 98
Hensby, C.N., 238, 247, 290
Heufler, C., 203
Higgs, G.A., 98
Hinterlang, E., 1
Hirschelmann, R., 93
Holmes, M.J.G., 287
Hooke, R., 113
Hopple, S., 310
Hubbs, S.J., 328
Humes, S.L., 310

Iacuzio, D.A., 371
Iannone, M.A., 278
Ikuta, H., 250, 269
Ishii, A., 32

Jagher, B., 235
Jensen, C., 79
Johnson, W.J., 348
Joseph, D., 195
Junien, J.L., 262

Katayama, K., 250, 269
Kawabe, H., 32
Kerr, J.S., 293
Keyzer, J.J., 54
Kheifets, J., 325
Kimball, E.S., 160
Kinkade, P., 387
Kobayashi, S., 250, 269
Kohno, Y., 167
Kosaka, Y., 32
Kossarek, L.M., 253, 272
Kostlan, C.R., 253
Kramer, K., 41
Krause, R.A., 366
Kuna, P., 26
Kusche, J., 1
Kutter, E., 223

Langrer, D., 54
Lazaro, E.J., 260, 297
Lazer, E.S., 257
Lees, R., 113
Lelièvre, V., 262
Leon, A., 79
Lewis, A.J., 231
Lokesh, B.R., 145
Lorenz, W., 1
Luginbuhl, B., 238

Mackin, W.M., 293
Maignan, J., 247
Maloff, B.L., 358
Mandecki, W., 366
Maresca, V., 121
Mariano, F., 72
Marks, R.L., 328
Marshall, W.S., 275
Matteo, M.R., 257, 387
May, S., 113
McAuley, F.T., 209
McMillan, R.M., 355
Meda, E., 72
Mehta, S.M., 38
Minonzio, F., 121
Mollison, K.W., 366
Montrucchio, G., 72
Moore, A.R., 299

Nakano, T., 384
Neugebauer, E., 1
Neumann, R.G., 160
Newton, R.C., 334
Nielsen, O.H., 191
Nielsen, S.T., 320

Norn, S., 79
Nytko, D., 361

O'Byrne, E.M., 341
O'Neill-Davis, L., 379
Oh-ishi, S., 384
Ohmann, Ch., 1
Okuyama, Shigeru, 130
Oliver, J.T., 257
Olsen, U.B., 177
Ongari, A.M., 121
Ono, H., 250
Oosting, E., 54
Otterness, I.G., 231, 371

Parmer, L.P., 297
Parnham, M.J., 232
Pasternak, R.D., 241, 328
Patel, K., 375
Pelosi, Jr., M.A., 297
Perin, A., 49
Perry, K., 331
Pettipher, E.R., 98
Pickett, W.C., 361, 382, 390
Pinter, G.W., 253
Pizzorno, J.E., 223
Popovic, S., 284
Possanza, G.J., 257
Prast, H., 203
Pratta, M.A., 334

Rainsford, K.D., 316, 337
Ramesha, C.S., 361, 382, 390
Rediske, J.J., 375
Regal, J.F., 363
Reynolds-Vaughn, R., 278
Richardson, F.J., 54
Rinkema, L.E., 83, 275
Roman, C., 275
Rordorf-Adam, Ch., 235
Rothschild, A.M., 62

Schade, R., 93
Schmal, A., 1
Schrier, D.J., 272
Schroder, H.C., 341
Schwender, C.F., 253
Scott, M.E., 253, 272
Sedgwick, A.D., 113
Seligmann, B., 375
Sessa, A., 49
Shirota, H., 250, 269
Shroot, B., 238, 247
Silbaugh, S.A., 83
Siminoff, P., 241
Simpson, J.G., 209
Sircar, J.C., 253, 272
Sorensen, J.R.J., 130
Soter, N., 382
Spillert, C.R., 260, 297
Spires, D.A., 325
Stahl Skov, P., 79
Stefano, C., 341
Stengel, P.W., 83
Stevens, T.M., 293
Stöltzing, H., 1
Strathy, G.M., 149
Sturm, R.J., 351
Suto, M.J., 253
Suwa, T., 167
Suzuki, A., 167
Svendsen, U.G., 79
Sweeney, F.J., 393

Taffer, I.M., 397
Terato, K., 250, 269
Terrell, T.G., 325
Tetta, C., 72
Thastrup, O., 79
Thomson, A.W., 209
Thon, K., 1
Timmermann, H., 41
Tomolonis, A.J., 314
Trimble, B.S., 281
Türker, R.K., 184

Urano, H., 167
Utsunomiya, I., 384

Vaigot, P., 290
Vargaftig, B.B., 195
Vassimon, C.S., 62
Venegoni, E., 121
Votta, B., 348

Wadopian, N.S., 241
Wadsworth, J., 323
Weber, D., 1
Weichman, B.M., 160, 351
Westmacott, D., 323
Whalen, J.D., 244
Whitesitt, C.A., 275
Whiting, P.H., 209
Willingham, W.M., 130
Willoughby, D.A., 287, 299
Wilson, B.D., 160
Wolberg, G., 278
Wolff, C.E., 303
Wolthers, B.G., 54
Wood, D.D., 160
Wooley, P. H., 244
Woronick, A., 387
Wrann, M., 145
Wright, J.V., 223
Wright, R.N., 241

Yamaki, K., 384
Yamasu, A., 384
Yamatsu, I., 250, 269
Yilmaz, G., 184
Young, J.M., 281, 314

Zanussi, C., 121
Zengil, H., 184
Zimmermann, J.L., 244
Zimmermann, T.P., 278
Zipkin, R.E., 397

Subject Index

Actions, pulmonary aerosol 83
1-0-Alkyl-2-20 : 4-sn-glycerol-3-phosphocholine specific phospholipase A2, 390
8-Amino-9-(2-thienyl-methyl)guanine (PF 119,229) 253, 272
5-Aminosalicylic acid anti-inflammatory moiety 191
Analgesic activity 130
Angiotensin II, effect 72
Antagonist, H_1 receptor 83
  –, H_1–H_2-receptor 72
  –, hydroxy-acetophenone leukotriene 275
Anti-inflammatory, activity of C_{10} 247
  –, agents 290, 306
  –, non-steroidal anti-inflammatory agents 130, 167, 250, 269
  –, benzimidazole derivative 257
Anthralin derivatives 247
Arachidonic acid 345
  –, anti-inflammatory agents 306
  –, bronchoconstrictor, metabolites 32

Arthritis, adjuvant-induced 241, 299
–, chronic 98
–, erosive 281
–, rheumatoid 266
–, selective activities 160
–, type II collagen-induced 244
Arthus pleurisy 351

Bronchoconstrictor arachidonic acid, metabolites 32

Catalase, effect 104
CGP 28237, anti-inflammatory pharmacologic profile 235
Chemotactic activity 323
Cholinesterase 38
Cyclooxygenase, inhibition 72
–, metabolism 397
Cyclosporin A-induced nephrotoxicity 209

Diamine oxidase activity 49
16,16-Dimethyl prostaglanin E_2, effect 310
Disodium cromoglycate, C5a-induced basophil degradulation 371
Drugs, anti-arthritic 348
–, anti-inflammatory 149, 316, 334, 337
–, anti-rheumatoid 89
–, effects 348

Endothelium, modulation 184
Endotoxin 177
Enzyme cholinesterase 38
Epstein Barr virus-induced B cell proliferation 266
Escherichia coli 366
Ethanol, toxicity 217
Etodolac 160, 244

FMLP-receptor 104, 177, 278
Fungus toxin orellanine, mode of action 203

Ganglioside 79
Gastrointestinal lesions 167

Histamine, blocking drugs 41
–, concentrations 66
–, fluorometric-fluoroenzymic 1
–, metabolism 54
–, release 26, 79
–, release factor 26
HWA 486, activity 241

Indomethacin 173, 266
–, induced ulcerogenesis in rates 314
Inflammation, acute 384
–, experimental 93
–, pertussis-induced air pouch 113
Inflammatory disease, therapeutic control 232
Inflammatory stimulus, 145
Interleukin-1 113, 323, 325, 328, 334, 337, 341, 345
Ischaemia, acute myocardial in rats 66

Kallikrein-kinin system, roles of 384

Leukemia, HL-60 cells 397, 400
Leukocytes, human 355
–, polymorphonuclear 361
Leukotriene antagonist 316
Leukotriene B_4, metabolism 275, 355
–, production 351
Levamisole, effect 266

Lipoxygenase products, metabolism 397
–, cyclooxygenase pathway 393
5-Lipoxygenase inhibitors, effect 316
LTB_4, binding 358
–, metabolism 361
LY 188695 (KB 2413) 83
Lymphocytes, activating factor 113
–, human 26

Macrophages, peritoneal 145
Mast cells 26, 32, 62, 79
Metal salts, protective effects 217
N-methoxy-3-(3,5-ditert-butyl-4-hydroxybenzylidene)-2-pyrrolidone (E-5110), in vitro effect 269
–, pharmacological properties 250
Mifentidine, analogues 41
Muramyl dipeptide 113

Nephrotoxicity, cyclosporin A-induced 209
Neutrophil oxidative metabolism 121
Nimesulide 121
Non-steroidal anti-inflammatory agents 130, 250, 269
Nordihydroguaiaretic acid 358
Nucleoside phosphorylase (PNP), inhibitors 253

Opioid receptor activity 130
Orellanine, mode of action 203
Oxatomide 32

PAF 72, 382
PAF, anti-inflammatory agents 306
PAF-acether 98
–, antagonists 195
PAF-induced mortality 379
Peptic ulcer 1
Phagocytic cell activation 375
Phorbol myristate acetate (PMA, TPA) 104, 290
–, acute lung inflammation 293
Phospholipase A_2, activation 345
Plasma renin activity 209
Platelets, ADP-deprived and aspirin-treated 195
Polymorphonuclear leukocyte, chemiluminescence 104
Prostaglandin biosynthesis 160
Prostaglandin E_2, metabolism 400
15-Prostaglandin dehydrogenase 397
Proteins, acute phase 113
Purine nucleoside phosphorylase, inhibitor 253, 272

Ranitidine, effect 38

Sulfamethoxazole, effect 260
Sulfasalazine, anti-inflammatory moiety 191
Sulfhydril compounds, synergism 217
Superoxidase dismutase, effect 104

12-0-Tetradecanoylphorbol-13-acetate (TPA) 104, 290, 293
Tilomisole, effect 266
Tixocortol 21 pivalate, transformation and metabolism 262
Toxal, inhibitor 278
Trimethoprim, effect 260
Trypsin-like activity 62
d-Tubocurarine, administration 54

Zinc citrate 223
–, gluconate 223
–, picolinate 223
–, salts, synergism of organic 217
Zymosan, anti-inflammatory agents 306